John Climaco, CEO of CNS Pharmaceuticals was recently a guest on Benzinga's All-Access.<br /><br />CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). <br /><br />The company’s lead drug candidate, Berubicin, is a novel drug that appears to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
